Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-03-22FDA Approved: BIMATOPROST — Original Application (Fosun Pharma USA Inc.)
The FDA approved the original application for bimatoprost, a generic ophthalmic solution manufactured by Fosun Pharma USA Inc., expanding ac…
-
FDA approval · 2019-03-12FDA Approved: ROCKLATAN — Original Application (Alcon Laboratories, Inc.)
The FDA approved ROCKLATAN as an original application for a fixed-dose combination ophthalmic solution of netarsudil 0.02% and latanoprost 0…
-
FDA approval · 2019-03-11FDA Approved: BRIMONIDINE TARTRATE — Original Application (Somerset Therapeutics, LLC)
FDA approved a generic Brimonidine tartrate ophthalmic product (Original Application) from Somerset Therapeutics, LLC to treat open-angle gl…
-
CLINICAL_TRIALS trial_result · 2019-02-26Clinical Trial Update: An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product [Phase 2]
Open-label extension study assessing safety of ForSight VISION5 product in Phase 2 for glaucoma conditions; completed with results posted in…
-
CLINICAL_TRIALS trial_result · 2019-02-26Clinical Trial Update: An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert [Phase 2]
Open-label extension to assess safety of the 13 mg bimatoprost ocular insert in patients with primary open-angle glaucoma or ocular hyperten…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-01-24FDA Approved: DORZOLAMIDE HYDROCHLORIDE — Original Application (Leading Pharma, LLC)
FDA approves the original application for dorzolamide hydrochloride as a generic ophthalmic medication indicated for open-angle glaucoma and…
-
CLINICAL_TRIALS trial_result · 2018-12-31Clinical Trial Update: A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension [Phase 1, Phase 2]
Clinical trial evaluating a fixed combination ocular insert for open-angle glaucoma or ocular hypertension has completed phases 1 and 2 with…
-
CLINICAL_TRIALS trial_result · 2018-12-03Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 [Phase 3]
Phase 3 trial evaluating CKD-351 for efficacy and safety in primary open-angle glaucoma and ocular hypertension.
-
CLINICAL_TRIALS trial_result · 2018-11-21Clinical Trial Update: Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial comparing BOL-303259-X ophthalmic solution to Timolol for open-angle glaucoma or ocular hypertension completed with results po…
-
FDA approval · 2018-11-20FDA Approved: BIMATOPROST — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for bimatoprost from Apotex Corp.
-
CLINICAL_TRIALS trial_result · 2018-11-15Clinical Trial Update: SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA) [Phase 4]
Phase 4 trial updating SIMBRINZA suspension as adjunctive therapy to prostaglandin analogues in open-angle glaucoma or ocular hypertension; …
-
CLINICAL_TRIALS trial_result · 2018-11-07Clinical Trial Update: Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial comparing BOL-303259-X with timolol in open-angle glaucoma or ocular hypertension has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2018-11-05Clinical Trial Update: Long-Term Non-Interventional Latanoprost Study
Long-term non-interventional trial of latanoprost completed; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-10-24Clinical Trial Update: Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) [Phase 4]
A Phase 4 trial comparing Combigan BID to Simbrinza TID in glaucoma and ocular hypertension; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-09-17Clinical Trial Update: Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension [Phase 4]
Phase 4 trial update assessing long-term safety of bimatoprost ophthalmic solution in glaucoma or ocular hypertension.
-
FDA approval · 2018-09-12FDA Approved: XELPROS — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves XELPROS (latanoprost) from Sun Pharmaceutical as a new ophthalmic solution for lowering intraocular pressure in open-angle glau…
-
CLINICAL_TRIALS trial_result · 2018-09-04Clinical Trial Update: BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension [Phase 2]
A Phase 2 clinical trial evaluating BOL-303259-X with Timolol 0.5% in subjects with open-angle glaucoma or ocular hypertension has completed…
-
CLINICAL_TRIALS trial_result · 2018-08-22Clinical Trial Update: Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial comparing safety and efficacy of T-2345 to Xalatan in primary open-angle glaucoma or ocular hypertension completed with posted…
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension [Phase 2]
Phase 2 clinical trial comparing safety and efficacy of the investigational BOL-303259-X to latanoprost in adults with glaucoma or ocular hy…
-
FDA approval · 2018-07-24FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE PRESERVATIVE FREE — Original Application (Aurobindo Pharma Limited)
FDA approved a preservative-free fixed-dose combination eye drop containing dorzolamide hydrochloride and timolol maleate as a generic produ…
-
FDA approval · 2018-07-16FDA Approved: TIMOPTIC-XE — Supplemental Application (Bausch & Lomb Incorporated)
The FDA approved a supplemental application for TIMOPTIC-XE (timolol maleate) from Bausch & Lomb Incorporated, authorizing changes to the pr…
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension [Phase 4]
Phase 4 trial update evaluating the safety of GANFORT ophthalmic solution in Chinese patients with open-angle glaucoma or ocular hypertensio…
-
FDA approval · 2018-06-11FDA Approved: VYZULTA — Supplemental Application (Bausch & Lomb Incorporated)
The FDA approved a supplemental application for VYZULTA (latanoprostene bunod) submitted by Bausch & Lomb Incorporated.
-
CLINICAL_TRIALS trial_result · 2018-06-11Clinical Trial Update: Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects [NA]
A completed clinical trial investigating the effects of latanoprost on choroidal blood flow regulation in humans, with intraocular pressure …
-
CLINICAL_TRIALS trial_result · 2018-06-06Clinical Trial Update: Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT [Phase 3]
Phase 3 long-term safety update for latanoprostene bunod ophthalmic solution 0.024% in Japanese subjects with open-angle glaucoma or ocular …